Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate
Expanding its portfolio, Eurocine Vaccines adds considerable value by the new HSV-2 vaccine candidate, which holds significant market potential. Currently, Herpes Simplex Virus Type 2, HSV-2, is mainly treated with antiviral drugs, and there is no effective therapeutic vaccine on the market. Eurocine Vaccines has now outlined a strategic development plan. The HSV-2 project offers a series of possibilities regarding the choice of technology and the opportunity it may give to pursue the therapeutic vaccine candidate with a prophylactic candidate to follow. Important decisions are to be made in